Skip to main content

Table 1 Demographic and clinical characteristics of the healthy control and disease groups

From: Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study

At blood sampling

HC (n = 50)

PsC (n = 200)

pPsA (n = 127)

PsSpA (n = 117)

AS (n = 157)

Median (IQR)

Median (IQR)

Median (IQR)

Median (IQR)

Median (IQR)

Age (years)

59.93 (51.44, 67.56)

54 (42, 65)

58.45 (50.31, 66.63)

59.53 (59.56, 66.54)

54.70 (44.52, 63.41)

Disease duration (years)

n/a

24 (16, 36.5)

15 (7, 26)

18 (9, 27)

22 (10, 31)

BMI (kg/m2)

n/a

n/a

29.04 (26.30, 32.84)

28.56 (26.06, 31.98)

27.07 (24.58, 30.13)

CRP (mg/dL)

n/a

n/a

2 (0, 5)

3 (2, 7)

4 (1, 10)

ASDAS (units)

n/a

n/a

2.1 (1.3, 2.7)

2.2 (1.5, 2.9)

2.1 (1.6, 2.9)

PASI (units)

n/a

4.8 (2.4, 8.8)

0.8 (0.0, 2.6)

0.8 (0.0, 2.8)

n/a

 

n (%)

n (%)

n (%)

n (%)

n (%)

Male sex

26 (52.00)

102 (51.00)

66 (51.97)

74 (63.25)

118 (75.16)

Anti-TNF use

n/a

26 (13.00)

47 (37.01)

53 (45.30)

59 (37.58)

HLA-B27 positive

n/a

n/a

9 (7.09)

47 (40.17)

140 (89.17)

  1. HC healthy control, PsC psoriasis without arthritis, pPsA peripheral PsA, PsSpA psoriatic spondyloarthropathy, AS ankylosing spondylitis, IQR interquartile range, n number/proportion, n/a not available/applicable, BMI body mass index, CRP C-reactive protein, ASDAS AS Disease Activity Score, PASI Psoriasis Area Severity Index, HLA human leucocyte antigen, Anti-TNF anti-tumour necrosis factor drug, sDMARD synthetic disease modifying anti-rheumatic drug